yttrium-90 monoclonal antibody 22A31

Yttrium-90 monoclonal antibody 22A31 is an investigational **C-ERC/mesothelin-targeted radiopharmaceutical radioimmunotherapy** consisting of the anti-mesothelin monoclonal antibody 22A31 labeled with the beta-emitting radionuclide yttrium-90. The agent is being developed in preclinical models for **malignant mesothelioma**, where it binds C-ERC/mesothelin expressed on tumor cells and delivers localized cytotoxic radiation to suppress tumor growth. Published mouse xenograft data showed tumor-selective accumulation of the corresponding imaging construct and therapeutic activity of the yttrium-90 conjugate in both subcutaneous and pleural dissemination mesothelioma models, supporting continued preclinical development.

Other names

yttrium-90 anti-C-ERC/mesothelin antibody 22A31yttrium-90 labeled mAb 22A31yttrium90 labeled mAb 22A31yttrium 90 labeled mAb 22A3190Y-labeled mAb 22A31